A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety
✍ Scribed by Jean-Pierre Olié; Brigitte Tonnoir; François Ménard; André Galinowski
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 141 KB
- Volume
- 24
- Category
- Article
- ISSN
- 1091-4269
- DOI
- 10.1002/da.20207
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo‐controlled trials (RCTs) and to infer the optimal duration of initial
Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (1
Transcranial magnetic stimulation (TMS) is a diagnostic method well established in neurology. As some effects of TMS are similar to those of electroconvulsive therapy (ECT), we looked for an antidepressant efficacy of TMS in a semi-blinded monocentric pilot study. Fifteen patients with Major Depress